Pathstone Holdings
TEVA icon

Pathstone Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Pathstone Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Buy
177,906
+13,903
+8% +$463K 0.02% 573
2026
Q1 		$4.94M Buy
164,003
+95,597
+140% +$3.08M 0.02% 574
2025
Q4 		$2.13M Buy
68,406
+522
+0.8% +$12.9K 0.01% 991
2025
Q3 		$1.37M Buy
67,884
+792
+1% +$13.9K 0.01% 1247
2025
Q2 		$1.12M Sell
67,092
-3,204
-5% -$51.7K ﹤0.01% 1327
2025
Q1 		$1.08M Sell
70,296
-4,357
-6% -$77.8K ﹤0.01% 1338
2024
Q4 		$1.65M Buy
74,653
+2,055
+3% +$37.4K 0.01% 1083
2024
Q3 		$1.31M Buy
72,598
+4,452
+7% +$77.9K 0.01% 1222
2024
Q2 		$1.11M Buy
68,146
+4,932
+8% +$76K 0.01% 1270
2024
Q1 		$892K Buy
63,214
+19,285
+44% +$243K ﹤0.01% 1351
2023
Q4 		$459K Buy
+43,929
New +$410K ﹤0.01% 1564

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pathstone Holdings's TEVA Position: Q2 2026 in Review

Pathstone Holdings increased its Teva Pharmaceuticals (TEVA) stake by 8.5% in Q2 2026, buying an estimated $463K and bringing the position to 177,906 shares worth $6.03M. The position accounts for 0.02% of the portfolio, ranked #573.

Pathstone Holdings first reported a position in TEVA in Q4 2023 and has held it in 11 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Pathstone Holdings held 177,906 shares of Teva Pharmaceuticals worth $6.03M as of Q2 2026.
  • Pathstone Holdings bought 13,903 Teva Pharmaceuticals shares in Q2 2026, an estimated $463K.
  • Teva Pharmaceuticals made up 0.02% of Pathstone Holdings's portfolio in Q2 2026, its #573 holding.
  • Pathstone Holdings first reported a position in Teva Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.